Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 29% primary Improvement Relative Risk Ventilation 28% primary Clinical status 25% Recovery time 25% Hospitalization time 29% Ameri et al. Melatonin for COVID-19 RCT ICU PATIENTS Is very late treatment with melatonin beneficial for COVID-19? RCT 226 patients in Iran (March - November 2021) Lower mortality (p<0.0001) and ventilation (p=0.0027) Ameri et al., Inflammopharmacology, doi:10.1007/s10787-022-01096-7 Favors melatonin Favors control
Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial
Ameri et al., Inflammopharmacology, doi:10.1007/s10787-022-01096-7
Ameri et al., Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial, Inflammopharmacology, doi:10.1007/s10787-022-01096-7
Nov 2022   Source   PDF  
  All Studies   Meta
RCT 226 ICU patients in Iran, showing lower mortality with melatonin treatment.
risk of death, 28.8% lower, RR 0.71, p < 0.001, treatment 73 of 109 (67.0%), control 110 of 117 (94.0%), NNT 3.7, primary outcome.
risk of mechanical ventilation, 27.6% lower, RR 0.72, p = 0.003, treatment 56 of 109 (51.4%), control 83 of 117 (70.9%), NNT 5.1, primary outcome.
clinical status, 25.0% lower, RR 0.75, p = 0.001, treatment 109, control 117, day 14.
recovery time, 25.0% lower, relative time 0.75, p = 0.04, treatment 109, control 117.
hospitalization time, 28.6% lower, relative time 0.71, p = 0.03, treatment 109, control 117.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ameri et al., 19 Nov 2022, Randomized Controlled Trial, Iran, peer-reviewed, 9 authors, study period 1 March, 2021 - 30 November, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial
Ali Ameri, Masoomeh Frouz Asadi, Ava Ziaei, Majid Vatankhah, Omid Safa, Manoochehr Kamali, Mohammad Fathalipour, Masoumeh Mahmoodi, Soheil Hassanipour
Inflammopharmacology, doi:10.1007/s10787-022-01096-7
Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The primary outcomes were mortality rate and requirement of IMV. The clinical status of patients was recorded at baseline and every day over hospitalization based on seven-category ordinal scale from 1 (discharged) to 7 (death). A total of 226 patients (109 in the melatonin group and 117 in the control group) were enrolled (median age; in melatonin group: 54.60 ± 11.51, in control group: 54.69 ± 13.40). The mortality rate was 67% in the melatonin group and 94% in the control group (OR; 7.75, 95% CI, 3.27-18.35, P < 0.001). The rate of IMV requirement was 51.4% in the melatonin group and 70.9% in the control group, for an OR of 2.31 (95% CI, 1.34-4.00, P < 0.001). The median number of days to hospital discharge was 15 days (13-17) in the melatonin group and 21 days (14-24) in the control group (OR; 5.00, 95% CI, 0.15-9.84, P = 0.026). Time to clinical status improvement by ≥ 2 on the ordinal scale in was 12 days (9-13) in the melatonin group and 16 days (10-19) in the control group (OR; 3.92, 95% CI, 1.69-6.14, P = 0.038). Melatonin significantly improved clinical status with a safe profile in patients with severe COVID-19 pneumonia.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10787-022-01096-7. Author contributions AA, AZ, and MF: conceptualization, methodology, software. MF, MM, and SH: data curation, writing-original draft preparation. MF, MV, OS, and MK: visualization, investigation. AAi: supervision. SH: software, validation. MF: writing-reviewing and editing. Declarations Conflict of interest None of the authors have a conflict of interest to disclose. Ethical approval and consent to participate Ethics approval was obtained from the ethics committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1399.526). The study was also undertaken in accordance with the guidelines of the Declaration of Helsinki and the principles of the International Conference on Harmonization Good Clinical Practice. Consent for publication A written informed consent was obtained from all patients. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Aisa-Alvarez, Soto, Guarner-Lans, Camarena-Alejo, Franco-Granillo et al., Usefulness of antioxidants as adjuvant therapy for septic shock a randomized clinical trial, Medicina (kaunas)
Al-Samkari, Leaf, Dzik, Carlson, Fogerty et al., COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection, Blood
Alamili, Bendtzen, Lykkesfeldt, Rosenberg, Gögenur, Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model, J Crit Care
Anderson, Maes, Gut dysbiosis dysregulates central and systemic homeostasis via suboptimal mitochondrial function: assessment, treatment and classification implications, Curr Top Med Chem
Anderson, Reiter, Melatonin: roles in influenza, Covid-19, and other viral infections, Rev Med Virol
Bahrampourjuybari, Pourhanifeh, Hosseinzadeh, Hemati, Mehrzadi, Melatonin potentials against viral infections including COVID-19: current evidence and new findings, Virus Res
Baloch, Baloch, Zheng, Pei, The Coronavirus disease 2019 (COVID-19) Pandemic, Tohoku J Exp Med
Bonilla, Valero, Chacín-Bonilla, Medina-Leendertz, Melatonin and viral infections, J Pineal Res
Bouck, Denorme, Holle, Middelton, Blair et al., COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity, Arterioscler Thromb Vasc Biol
Camp, Bai, Gonullu, Nayak, Hm, Melatonin interferes with COVID-19 at several distinct ROS-related steps, J Inorg Biochem
Can, Ulugöl, Güneş, Aksu, Tosun et al., Effects of alprazolam and melatonin used for premedication on oxidative stress, glicocalyx integrity and neurocognitive functions, Turk J Anaesthesiol Reanim
Cichoz-Lach, Celinski, Konturek, Konturek, Slomka, The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis, J Physiol Pharmacol
Cook, Mascolo, Bass, Duffy, Zehring et al., Has COVID-19 Complicated eating disorder treatment? An examination of comorbidities and treatment response before and during the COVID-19 pandemic, Prim Care Companion CNS Disord
Davoudi-Monfared, Rahmani, Khalili, Hajiabdolbaghi, Salehi et al., A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19, Antimicrob Agents Chemother
Dequin, Heming, Meziani, Plantefève, Voiriot et al., Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients With COVID-19: a randomized clinical trial, JAMA
Dianatkhah, Najafi, Sharifzadeh, Ahmadi, Sharifnia et al., Melatonin supplementation may improve the outcome of patients with hemorrhagic stroke in the intensive care unit, J Res Pharm Pract
Fogleman, Cohen, Mercier, Farrell, Rutz et al., A pilot of a randomized control trial of melatonin and vitamin C for mild-to-moderate COVID-19, J Am Board Fam Med
Foley, Steel, Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence, Complement Ther Med
Galley, Lowes, Allen, Cameron, Aucott et al., Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis, J Pineal Res
Gitto, Karbownik, Reiter, Tan, Cuzzocrea et al., Effects of melatonin treatment in septic newborns, Pediatr Res
Hasan, Atrakji, Mehuaiden, The effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients, Int J Infect Dis
Henderson, Kim, Lee, Use of melatonin as adjunctive therapy in neonatal sepsis: a systematic review and meta-analysis, Complement Ther Med
Iversen, Dahm, Skretting, Mowinckel, Stranda et al., Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study, Thromb Haemost
Kleszczyński, Slominski, Steinbrink, Reiter, Clinical trials for use of melatonin to fight against COVID-19 are urgently needed, Nutrients
Kronstein-Wiedemann, Stadtmüller, Traikov, Georgi, Teichert et al., SARS-CoV-2 infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism, Stem Cell Rev Rep
Lissoni, Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms, Ann N Y Acad Sci
Marzougui, Hammouda, Bendhia, Maaloul, Agrebi et al., Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients, Int Urol Nephrol
Mazeraud, Jamme, Mancusi, Latroche, Megarbane et al., Intravenous immunoglobulins in patients with COVID-19-associated moderate-tosevere acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial, Lancet Respir Med
Nair, Perioperative melatonin in COVID-19 patients: benefits beyond sedation and analgesia, Med Gas Res
Rahmani, Davoudi-Monfared, Nourian, Khalili, Hajizadeh et al., Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial, Int Immunopharmacol
Reiter, Ma, Sharma, Treatment of ebola and other infectious diseases: melatonin "goes viral, Melatonin Res
Rodríguez-Rubio, Figueira, Acuña-Castroviejo, Borobia, Escames et al., A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial, Arch Med Res
Seely, Legacy, Auer, Fazekas, Delic et al., Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): a randomized placebo controlled clinical trial, EClinicalMedicine
Sen, Deficient synthesis of melatonin in COVID-19 can impair the resistance of coronavirus patients to mucormycosis, Med Hypotheses
Shiu, Reiter, Tan, Pang, Urgent search for safe and effective treatments of severe acute respiratory syndrome: is melatonin a promising candidate drug?, J Pineal Res
Shneider, Kudriavtsev, Vakhrusheva, Can melatonin reduce the severity of COVID-19 pandemic?, Int Rev Immunol
Wirtz, Bärtschi, Spillmann, Ehlert, Känel, Effect of oral melatonin on the procoagulant response to acute psychosocial stress healthy men: a randomized placebo-controlled study, J Pineal Res
Zhang, Li, Grailer, Wang, Wang et al., Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome, J Pineal Res
Zhang, Wang, Ni, Di, Ma et al., COVID-19: melatonin as a potential adjuvant treatment, Life Sci
Zisapel, New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation, Br J Pharmacol
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop